About Absci Corp
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.absci.com/
Frequently Asked Questions
What is the 52-week range for ABSI?
The 52-week high is $12.055 and the 52-week low is $2.24.
What is the P/E ratio for ABSI?
The P/E ratio data is currently unavailable.
What is the dividend yield for ABSI?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -59.21%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -7756.37%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.77.
Analyst Recommendation Trends
Wall Street analyst consensus for ABSI over the last few months:
Latest ABSI News
Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress
Beam Therapeutics (BEAM) stock analysis: BEAM-302 gene-editing upside for 2028â2029, cash runway/dilution risks, valuation vs peersâread now.
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial in mid-2027 VANCOUVER, Wash. and NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced additional details for the company’s planned global, multi-center
Needham Reiterates Buy on Absci, Maintains $11 Price Target
Needham analyst Gil Blum reiterates Absci (NASDAQ:ABSI) with a Buy and maintains $11 price target.
Absci (ABSI) Stock Looks Expensive Against Its Book Value
Absci has seen its share price move sharply in recent years, which puts a spotlight on whether the current US$9.82 level is supported by the company’s book value. For anyone looking at the stock today, the key issue is how that accounting base stacks up against the recent share price performance. Over the past 3 years, Absci has delivered a very large share price gain, which raises the question of how much of that move is mirrored in the company’s underlying net assets. The business model...
Recursion Pharmaceuticals Highlights AI Drug Platform, FAP Progress at Morgan Stanley Conference
Recursion Pharmaceuticals (NASDAQ:RXRX) outlined its strategy, clinical pipeline and partnership progress at Morgan Stanley’s Global Healthcare Conference, with CEO and President Najat Khan emphasizing the company’s shift toward an end-to-end, AI-enabled drug discovery and development platform. Kha
Vicor, Arm Holdings, Micron Technology And Other Big Stocks Moving Higher On Thursday
U.S. stocks rose; Vicor jumped 13.5% on a new license, while Generac surged 19.6% on an Amazon deal. Securitize and biotech shares rallied.
Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Absci Corporation (ABSI) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 7:45 AM EDTCompany ParticipantsSean McClain - Founder,...
Baldness Drug Stocks like Veradermics (MANE) and Absci (ABSI) Are Chasing the Same Wall Street Magic as Ozempic
Bloomberg reported on August 29 that hair-loss drug stocks are surging as Wall Street bets on a new pharmaceutical goldmine following the GLP-1 weight-loss boom. Shares of Veradermics, Incorporated (NYSE:MANE) have climbed nearly 500% since its February 2026 initial public offering, while Absci Corporation (NASDAQ:ABSI)’s stock has more than doubled so far in 2026. Switzerland’s […]
Eli Lilly Utilizes Weight-Loss Drug Profits To Fund Women's Health Initiatives: Report
Eli Lilly is expanding into women's health, targeting endometriosis and pregnancy disorders by hiring experts and strategic investments.
Absci's Billion-Dollar Hair Bet: Why The AI Story Doesn't Add Up
Absci is rated SELL, as its valuation is highly concentrated on ABS-201 with limited partner revenue and an early-stage pipeline. Click for more on ABSI.
Absci: Positive Ph1 Data ABS-201 AGA And Several Catalysts Inbound (Upgrade)
Absci is upgraded to Buy after strong Phase 1 ABS-201 AGA data, solid PK/safety, and 2026â27 catalysts. Read the latest analysis on the stock here.
BTIG Maintains Buy on Absci, Raises Price Target to $16
BTIG analyst Kambiz Yazdi maintains Absci (NASDAQ:ABSI) with a Buy and raises the price target from $13 to $16.
AI in Drug Discovery Market Projected to Reach $8.52 Billion By 2030
Equity Insider News Commentary - Pharmaceutical research is being rebuilt around artificial intelligence faster than the industry can absorb it. Arizton values the global AI in drug discovery market at approximately $1.71 billion in 2024 and projects it will reach roughly $8.52 billion by 2030, a compound annual growth rate of about 30.58%. That is a market compounding at more than double the rate of most enterprise software categories, and it is being spent inside an industry that already inves
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-31 | Jonasson Zachariah | -8,320 | $8.71 | $72,467 |
| 2026-08-03 | Somaratne Ransi Mudalinayake | +383,000 | - | - |
| 2026-06-30 | Szela Mary T | +12,900 | $11.54 | $148,866 |
| 2026-06-24 | McClain Sean | -59,896 | $10.075 | $603,452 |
| 2026-06-04 | Szela Mary T | +33,200 | - | - |
| 2026-06-04 | Szela Mary T | +8,400 | - | - |
| 2026-06-04 | MCGINNIS KAREN K | +39,800 | - | - |
| 2026-06-04 | MCGINNIS KAREN K | +10,100 | - | - |
| 2026-06-04 | Pangalos Menelas N | +39,800 | - | - |
| 2026-06-04 | Pangalos Menelas N | +10,100 | - | - |
| 2026-06-04 | VAN HOUTEN FRANS | +39,800 | - | - |
| 2026-06-04 | VAN HOUTEN FRANS | +10,100 | - | - |
| 2026-06-04 | Sirosh Joseph | +39,800 | - | - |
| 2026-06-04 | Sirosh Joseph | +10,100 | - | - |
| 2026-06-04 | Szela Mary T | +39,800 | - | - |
| 2026-06-04 | Szela Mary T | +10,100 | - | - |
| 2026-06-04 | Rabinovitsj Daniel A | +39,800 | - | - |
| 2026-06-04 | Rabinovitsj Daniel A | +10,100 | - | - |
| 2026-05-31 | Jonasson Zachariah | -8,319 | $6.75 | $56,153 |
| 2026-05-13 | Pangalos Menelas N | +37,453 | $5.36 | $200,748 |
| 2026-03-12 | Busch Andreas | +100,000 | $2.29 | $229,000 |
| 2026-03-03 | Somaratne Ransi Mudalinayake | +650,000 | - | - |
| 2026-03-03 | Walker Shelby J. | -9,825 | $2.8 | $27,510 |
| 2026-03-03 | Jonasson Zachariah | -10,848 | $2.8 | $30,374 |
| 2026-03-03 | Bedrick Todd | -5,282 | $2.8 | $14,790 |
| 2026-03-03 | McClain Sean | -25,316 | $2.8 | $70,885 |
| 2026-03-03 | Walker Shelby J. | -9,825 | $2.8 | $27,510 |
| 2026-03-03 | McClain Sean | -25,316 | $2.8 | $70,885 |
| 2026-03-03 | Bedrick Todd | -5,282 | $2.8 | $14,790 |
| 2026-03-03 | Jonasson Zachariah | -10,848 | $2.8 | $30,374 |
| 2026-03-03 | Busch Andreas | -1,257 | $2.8 | $3,520 |
| 2026-03-02 | Walker Shelby J. | +356,300 | - | - |
| 2026-03-02 | Walker Shelby J. | +90,300 | - | - |
| 2026-03-02 | Jonasson Zachariah | +534,400 | - | - |
| 2026-03-02 | Jonasson Zachariah | +135,400 | - | - |
| 2026-03-02 | Bedrick Todd | +195,900 | - | - |
| 2026-03-02 | Bedrick Todd | +49,600 | - | - |
| 2026-03-02 | McClain Sean | +1,603,200 | - | - |
| 2026-03-02 | McClain Sean | +406,200 | - | - |
| 2026-03-02 | Pangalos Menelas N | +22,800 | - | - |
| 2026-03-02 | Pangalos Menelas N | +5,800 | - | - |
| 2026-03-02 | Walker Shelby J. | +356,300 | - | - |
| 2026-03-02 | Walker Shelby J. | +90,300 | - | - |
| 2026-03-02 | McClain Sean | +1,603,200 | - | - |
| 2026-03-02 | McClain Sean | +406,200 | - | - |
| 2026-03-02 | Bedrick Todd | +195,900 | - | - |
| 2026-03-02 | Bedrick Todd | +49,600 | - | - |
| 2026-03-02 | Jonasson Zachariah | +534,400 | - | - |
| 2026-03-02 | Jonasson Zachariah | +135,400 | - | - |
| 2026-03-02 | Jonasson Zachariah | -8,307 | $2.74 | $22,761 |
| 2026-02-27 | Pangalos Menelas N | +75,095 | $2.74 | $205,760 |
| 2026-02-23 | McClain Sean | -396,399 | - | - |
| 2026-02-23 | McClain Sean | -267,008 | $2.65 | $707,571 |
| 2026-02-23 | McClain Sean | +396,399 | $1.21 | $479,643 |
| 2026-02-03 | Busch Andreas | -1,469 | $2.99 | $4,392 |
| 2026-02-02 | Jonasson Zachariah | -17,496 | $2.99 | $52,313 |
| 2026-02-02 | McClain Sean | -26,761 | $2.99 | $80,015 |
| 2026-02-02 | McClain Sean | -26,761 | $2.99 | $80,015 |
| 2026-02-02 | Jonasson Zachariah | -17,496 | $2.99 | $52,313 |
| 2026-02-02 | Bedrick Todd | -3,659 | $2.99 | $10,940 |
| 2026-01-28 | Bedrick Todd | +59,400 | - | - |
| 2026-01-28 | Bedrick Todd | +15,000 | - | - |
| 2025-12-05 | VAN HOUTEN FRANS | +40,000 | $3.72 | $148,800 |
| 2025-11-30 | Jonasson Zachariah | -8,320 | $3.17 | $26,374 |
| 2025-10-14 | McClain Sean | -23,293 | $3.68 | $85,718 |
| 2025-10-14 | Jonasson Zachariah | -387 | $3.68 | $1,424 |
| 2025-10-14 | Busch Andreas | -3,092 | $3.68 | $11,379 |
| 2025-10-14 | Bedrick Todd | -21,950 | $3.68 | $80,776 |